+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID04628026

Randomized Phase 3 Study of Venetoclax With Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Acute Myeloid Leukemia or MDS-EB-2

Led by University of Ulm · Updated on 2026-11-03

650

Participants Needed

91

Research Sites

152 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase 3 clinical trial to assess the effects of adding venetoclax to standard chemotherapy in adults newly diagnosed with acute myeloid leukemia AML or myelodysplastic syndrome with excess blasts-2 MDS-EB-2. The study includes a dose-escalation phase to determine the optimal venetoclax dose before randomizing patients to receive either venetoclax with chemotherapy or placebo with chemotherapy. The goal is to evaluate treatment safety and effectiveness in this patient group. Participants will receive two cycles of induction chemotherapy combined with either venetoclax or placebo. Those who achieve complete remission CR, complete remission with incomplete hematologic recovery CRi, or morphologic leukemia-free state MLFS after induction may continue with consolidation chemotherapy according to standard regimens or investigator choice. Some patients may proceed to allogeneic hematopoietic cell transplantation HCT based on disease characteristics and individual assessment. During the study, participants will be closely monitored through clinical evaluations, including survival rates, remission rates, relapse rates, and quality of life questionnaires. Safety assessments will focus on dose-limiting toxicities during the initial cycles. The study includes long-term follow-up to assess overall survival and event-free survival, with the total duration extending up to approximately ten years after enrollment of the last patient.

CONDITIONS

Brief Title

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Research Team

H

Hartmut Doehner, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here